PERY 21.95 Perry Ellis International Inc $PERY Hit a 52

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
PERY 21.95 Perry Ellis International Inc $PERY Hit a 52 week high of 22.28 Currently at 21.95 -0.05 -0.23% With a day low of 21.89 and a total volume of 7,385.

PERY Perry Ellis International Inc Recent Headline News

Perry Ellis International Announces Luggage Partnership With UGA Fashion
GlobeNewswire - Mon Nov 10, 8:00AM CST
Perry Ellis International, Inc. (Nasdaq ERY) announced today that it has entered into a new license agreement with UGA Fashion S.A. de C.V. to design, manufacture and market men's and women's luggage, travel bags, back packs and travel accessories ("luggage line" under the Perry Ellis(R) brand in Mexico.
PERY: 21.85 (-0.15)

Uptrend Call Working As Perry Ellis Stock Rises 21.6% (PERY)
Comtex SmarTrend(R) - Tue Nov 04, 9:45AM CST
SmarTrend identified an Uptrend for Perry Ellis (NASDAQ ERY) on May 22nd, 2014 at $16.59. In approximately 6 months, Perry Ellis has returned 21.58% as of today's recent price of $20.17.
PERY: 21.85 (-0.15)

Perry Ellis Up 21.0% Since SmarTrend Uptrend Call (PERY)
Comtex SmarTrend(R) - Tue Oct 28, 9:15AM CDT
SmarTrend identified an Uptrend for Perry Ellis (NASDAQ ERY) on May 22nd, 2014 at $16.59. In approximately 5 months, Perry Ellis has returned 21.04% as of today's recent price of $20.08.
PERY: 21.85 (-0.15)

26.6% Return Seen to Date on SmarTrend Perry Ellis Call (PERY)
Comtex SmarTrend(R) - Mon Oct 20, 5:01PM CDT
SmarTrend identified an Uptrend for Perry Ellis (NASDAQ ERY) on May 22nd, 2014 at $16.59. In approximately 5 months, Perry Ellis has returned 26.64% as of today's recent price of $21.01.
PERY: 21.85 (-0.15)

SUPERVALU Q2 Earnings in Line, Revenues Beat on Comps - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 9:30AM CDT
SUPERVALU Inc.'s (SVU) second-quarter fiscal 2015 earnings per share of 11 cents were in line with the Zacks Consensus Estimate but declined 15.4% from the prior-year quarter figure of 13 cents.
PERY: 21.85 (-0.15), SVU: 8.66 (+0.04), GIL: 57.96 (-0.86), VFC: 70.52 (+0.73)

Estee Lauder to Boost Fragrance Portfolio with Le Labo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 3:00PM CDT
Estee Lauder Companies Inc. (EL) recently inked a definitive agreement to take over high-end fragrance and lifestyle brand Le Labo (The Lab) to strengthen its fragrance category.
PERY: 21.85 (-0.15), GIL: 57.96 (-0.86), VFC: 70.52 (+0.73), EL: 72.88 (+0.30)

Helen of Troy Posts In Line Q2 Earnings; Beats on Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:20AM CDT
Helen of Troy Limited (HELE) reported second-quarter fiscal 2015 adjusted earnings of 99 cents, up 2.1% from the year-ago level.
HELE: 63.39 (-0.65), PERY: 21.85 (-0.15), GIL: 57.96 (-0.86), VFC: 70.52 (+0.73)

Original Penguin Announces New International Partnership With Kiona
GlobeNewswire - Tue Oct 14, 8:00AM CDT
Perry Ellis International, Inc. (PEI) (Nasdaq ERY) announced today that it has entered into a new license agreement with Kiona S.A. de C.V. to market men's and women's bags, messenger bags, IT carriers, camping bags, small leather goods, sports bags, travel bags, utility bags, backpacks, key chains and cosmetic bags under the Original Penguin(R) brand in Mexico.
PERY: 21.85 (-0.15)

Shares of PERY Up 20.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 13, 11:05AM CDT
SmarTrend identified an Uptrend for Perry Ellis (NASDAQ ERY) on May 22nd, 2014 at $16.59. In approximately 5 months, Perry Ellis has returned 20.37% as of today's recent price of $19.97.
PERY: 21.85 (-0.15)

Perry Ellis Shares Up 23.1% Since SmarTrend's Buy Recommendation (PERY)
Comtex SmarTrend(R) - Mon Oct 06, 9:43AM CDT
SmarTrend identified an Uptrend for Perry Ellis (NASDAQ ERY) on May 22nd, 2014 at $16.59. In approximately 5 months, Perry Ellis has returned 23.09% as of today's recent price of $20.42.
PERY: 21.85 (-0.15)

Columbia Sportswear Launches PED TurboDown Jackets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 03, 1:40PM CDT
Columbia Sportswear Inc. (COLM) launched its first Performance Enhanced Down (PED) insulating jacket, TurboDown.
PERY: 21.85 (-0.15), VFC: 70.52 (+0.73), COLM: 40.33 (-0.08), HBI: 110.64 (+1.31)

Perry Ellis International to Participate in Deutsche Bank Finance Leveraged Conference
GlobeNewswire - Thu Sep 25, 8:00AM CDT
Perry Ellis International, Inc. (Nasdaq ERY) announced today that the company will participate in the Deutsche Bank Finance Leveraged Conference on Tuesday, September 30, 2014 at the Phoenician Hotel in Scottsdale, AZ. A webcast of this presentation will be available live at the company's website (http://www.pery.com) and for 15 days following the conference.
PERY: 21.85 (-0.15), DB: 29.95 (-0.29)

Guess? (GES) Woes to Continue: Should You Dump It Now? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 9:36AM CDT
On Sep 17, 2014, we issued an updated research report on Guess? Inc. (GES). The apparel retailer reported dismal second-quarter fiscal 2015 results on Aug 28.
GES: 21.45 (-0.30), PERY: 21.85 (-0.15), ANF: 28.54 (-0.96), KORS: 69.78 (-0.17)

Perry Ellis International Expands Partnership With American Traveler
GlobeNewswire - Thu Sep 18, 9:34AM CDT
Perry Ellis International, Inc. (PEI) (Nasdaq ERY) announced today that it is expanding its license agreement with American Traveler, Inc. granting rights under the Pro Player(R) brand to include sport duffels, backpacks, messenger bags, tote bags and sack packs.
PERY: 21.85 (-0.15)

Can Perry Ellis International (PERY) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:42AM CDT
Perry Ellis International has a solid Zacks Rank to a positive Earnings ESP and a positive earnings surprise happens nearly 70% of the time and so it is expected to deliver another beat in the next report.
PERY: 21.85 (-0.15)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aroa Biosurgery Reports Low Infection Rates: A Milestone

Updated Category News Views 1

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Continue Reading
Harbour BioMed Joins Stock Connect, Boosts Investor Access

Updated Category News Views 3

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Continue Reading
Clover's RSV Combo Vaccine Shows Promise in Trials

Updated Category News Views 1

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 12

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
ATTACK SHARK Partners with Cloud9 League Team

Updated Category News Views 2

Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...

Continue Reading
Zendure, SolarFlow Pro Win Big at IFA 2026 Tech Awards

Updated Category News Views 2

Trophy Time for Zendure in Berlin The Berlin Chronicles of 2026 tell an interesting tale for Zendure—a tale where top honors and glowing recognition highlight its efforts in the sustainable energy arena. At the Global Product Technology Innovation Awards, Zendure's SolarFlow 4000 Mix Pro snagged the Gold for Sustainable Home Energy Storage System. Not only that, but...

Continue Reading
Media Forum Spotlights Asia-Pacific Cooperation

Updated Category News Views 3

The Opening Scene: A Gathering with Purpose Well, here we go, diving right into the latest shindig in Shenzhen at the Asia-Pacific Media Forum. Held in China's Guangdong province, they've rounded up over 400 reps from every corner of the globe, all chewing over one key theme: "Building a Path to Shared Prosperity for the Asia-Pacific Community." You could say it's a step...

Continue Reading
Fosun Pharma Hits the Buyback Button: What's Next?

Updated Category News Views 0

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 3

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading

Top 5 Most Recently Viewed Articles

Prologis Earnings Report: Investors' Key Insights and Analysis

Updated Category News Views 138

Understanding Prologis's Upcoming Quarterly Earnings Prologis (NYSE: PLD) is set to release its latest quarterly earnings report, and investors are eagerly awaiting the insights it will provide. As the company approaches its earnings announcement, analysts project an earnings per share (EPS) of $1.02, which serves as a benchmark for performance expectations. Investor...

Continue Reading
How Changing U.S. Jobs Report Affects Market Dynamics

Updated Category News Views 171

The recent U. S. employment report sent shockwaves through financial markets, reshaping how traders and investors eyed their portfolios. Stronger-than-expected job creation—with figures soaring over 100,000—meant one thing: the narrative on interest rates was about to change. Gone were the days of comfortably betting on rate cuts; now, everyone’s scrambling to...

Continue Reading
Suno Boosts Innovation for Creators by Acquiring WavTool

Updated Category News Views 157

Suno Boosts Innovation for Creators by Acquiring WavTool Suno has recently made a significant move in the music industry with their acquisition of WavTool. This strategic decision aims to enhance their offerings for songwriters and producers, enabling them to create music that resonates with a broader audience. By integrating WavTool's advanced capabilities into their...

Continue Reading
Leqembi's New IV Treatment Approval: A Milestone for Alzheimer’s Care

Updated Category News Views 274

Leqembi Approved for IV Maintenance Treatment BioArctic AB, a notable player in the biopharmaceutical sector, has made significant headlines with the approval of Leqembi (lecanemab) for intravenous (IV) maintenance treatment for Alzheimer’s disease in the United Kingdom. This groundbreaking decision was announced following rigorous evaluations by the Medicines and...

Continue Reading
Investors of ATYR, MLTX, BAX, and JHX Have Legal Options

Updated Category News Views 145

Overview of Class Action Lawsuits for ATYR, MLTX, BAX, JHX Attention investors! If you’ve invested in aTyr Pharma Inc. (NASDAQ: ATYR), MoonLake Immunotherapeutics (NASDAQ: MLTX), Baxter International, Inc. (NYSE: BAX), or James Hardie Industries plc (NYSE: JHX), it’s important to be aware of significant class action lawsuits affecting your investments. These companies...

Continue Reading